Saturday, 30 November 2013

Reportstack Year End Offers on Market Research Reports

Reportstack has announced multiple offers as part of End of Year deals. 
1. Pharma Country Series Bundle Offers

      -  Buy Entire country set and get 50% off
      -  Buy any 3 countries and get 35% off
      -  Buy one country and get 20% off
To know the reports included in this bundle offer please visit http://www.reportstack.com/product/146806/reportstack-year-end-offers-on-pharma-country-series-reports.html for details.
2. Reportstack Pipeline Review Reports- HI 2013 & H2 2013 Offer

Buy 1 get another for half price.

3. 200+ Oil &Gas, Power & Alternative Energy, Nuclear Energy, Clean Technology, Chemicals, Technology and Mining Industry Reports for $8000

4. To know other offers please visit
Contact:
Debora White
Online Marketing Executive
Email: contactus@reportstack.com
Phone: +1-888-789-6604
http://www.reportstack.com






PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update


Reportstack has announced a new market report on PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

US physicians surveyed for this report state that they may follow guidelines such as ACR, but also follow their own clinical experience to treat patients. In the US, about 75% of patient referrals come from Primary Care Physicians (PCPs). Also, most patients who are referred present with signs and symptoms of moderate to severe RA. People seeking treatment are generally in the 55 and older age group. Within this age group, females outnumber men by a small margin.

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the United States including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in United States from 2011 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the United States rheumatoid arthritis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in the United States
- Obtain sales forecast from 2011-2022 in the United States


To view the table of contents and know more details please visit PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update report. 

Similar Reports:

PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.

The report expects the PsO pipeline to begin launching hopefuls in 2015, starting with Novartis’ secukinumab and Celgene’s apremilast. The following year, Merck’s MK-3222, Lilly’s ixekizumab, Pfizer’s Xeljanz, and Amgen’s brodalumab will emerge, thus jamming the PsO market and making it difficult for each drug to gain market share.

Scope

- Overview of Psoriasis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK Psoriasis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in the UK.

To view the table of contents and know more details please visit PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Psoriasis - US Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on PharmaPoint: Psoriasis - US Drug Forecast and Market Analysis to 2022. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.

The US is the largest PsO market, although it does not have the highest prevalence of the disease. The report estimates that the US generated approximate sales in 2012. J&J’s Stelara has been impressive since launching in 2009, and claimed close the patient share compared with its company counterpart, Remicade, which only drew less in 2012. Since Stelara’s cost per day is the highest of the biologics, which is three times that of Remicade, it did not take a lot of patient share to generate comfortable annual sales close in 2012.

Scope

- Overview of Psoriasis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Psoriasis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in the US.

To view the table of contents and know more details please visit PharmaPoint: Psoriasis - US Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b), Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), and Teva’s Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

The US is the largest MS market due to the high prevalence of the disease and comparatively high MS drug prices.During the forecast period, the major driver for market growth is an increase in the diagnosis rate following adoption of the revised 2010 McDonald criteria, which greatly reduced the time to diagnosis, and the push by physicians for the earlier initiation of treatment in patients. Other important drivers include the launch of several pipeline DMTs that provide improved efficacy and convenient administration, as well as increased accessibility to treatment due to US healthcare reform, which will both result in higher treatment rates. Furthermore, the launch of novel DMTs that specifically target progressive MS, such as masitinib and siponimod, will also increase treatment uptake by patients with PPMS or SPMS. With several key patent expiries of leading branded products occurring throughout the forecast period, generic erosion will be the biggest barrier to market growth.

Scope

- Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Multiple Sclerosis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the US

To view the table of contents and know more details please visit PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b), Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), and Teva’s Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

MS has a low prevalence in India, which could be due to genetics or environmental factors. However, many physicians surveyed for this report mostly use the Poser criteria to diagnose patients, given the lack of current accessibility to sensitive diagnostic tools, such as MRI. Therefore, it is possible that the current rate of MS in India is grossly underestimated, meaning a large proportion of undiagnosed MS patients are not captured and provided adequate treatment. The major drivers of growth in this market will be the launch of oral DMTs and an increase in availability of advanced diagnostic tools, which will likely lead to increased diagnosis and treatment rates over the forecast period.

Scope

- Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting India Multiple Sclerosis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in India.

To view the table of contents and know more details please visit PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Alzheimer’s Disease - Japan Drug Forecast and Market Analysis to 2022


Reportstack has announced a new market report on PharmaPoint: Alzheimer’s Disease - Japan Drug Forecast and Market Analysis to 2022. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease._x000D_

Aricept is a home-grown product in Japan, and Eisai offers its highest-selling product in additional dosage forms and strengths, which may contribute its rising sales figures. Arimenda will be the first pipeline product to reach the Japanese market and will sustain modest sales throughout the forecast period due to competition from the launch of novel products.

Scope

- Overview of Alzheimer’s Disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape._x000D_
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis._x000D_
- Sales forecast for the top drugs in Japan from 2012-2022._x000D_
- Analysis of the impact of key events as well the drivers and restraints affecting Japan Alzheimer’s Disease market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return_x000D_
- Stay ahead of the competition by understanding the changing competitive landscape for Alzheimer’s Disease_x000D_
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential_x000D_
- Make more informed business decisions from insightful and in-depth analysis of drug performance _x000D_
- Obtain sales forecast for drugs from 2012-2022 in Japan.


To view the table of contents and know more details please visit PharmaPoint: Alzheimer’s Disease - Japan Drug Forecast and Market Analysis to 2022 report. 

Similar Reports: